News | Brachytherapy Systems | March 06, 2017

Single Escalated Brachytherapy Dose May Be Safe and Effective for Localized Prostate Cancer

Option for high-dose-rate brachytherapy marries efficacy of implant-based therapy and convenience of a single treatment

prostate cancer, radiation therapy, high-dose-rate brachytherapy, HDR, Red Journal study

This is a single-fraction high-dose-rate prostate implant imaging and dosimetry. Image courtesy of Daniel Krauss/American Society for Radiation Oncology (ASTRO)

March 6, 2017 — Results from a new prospective clinical trial indicate high-dose-rate (HDR) brachytherapy administered in a single, 19 Gy treatment may be a safe and effective alternative to longer HDR courses for men with localized prostate cancer. The study is available online in the International Journal of Radiation Oncology, Biology, Physics, the flagship journal of the American Society for Radiation Oncology (ASTRO).

With brachytherapy, also known as internal radiation therapy (RT), implants are surgically inserted in or near cancerous tissue to deliver a curative radiation dose directly to the tumor while limiting exposure for surrounding healthy tissue. Reducing this exposure is of particular concern for treating tumors in the prostate, which is surrounded by multiple critical structures. In contrast to low-dose-rate (LDR) brachytherapy, where radioactive seed implants are placed permanently in the body and gradually deposit low levels of radiation over a period of months, HDR treatments deposit the dose in one treatment, after which the radioactive implant is removed from the patient.

Typically, HDR brachytherapy is administered in four to as many as nine treatment sessions, which generally requires multiple invasive procedures to insert the implants. While the number of sessions can be streamlined by increasing the dose given in each session, data on the safety and tolerability of highly escalated brachytherapy doses are still relatively new and therefore limited. In this study, researchers found patients who received a single fraction of 19 Gy HDR brachytherapy experienced similar clinical outcomes as with LDR brachytherapy, but with the convenience of a single visit.

“It is becoming apparent that patients may be treated definitively for their prostate cancer in as little as a single day with a minimally invasive outpatient procedure,” said lead study author Daniel J. Krauss, M.D., a radiation oncologist at Oakland University’s William Beaumont School of Medicine in Royal Oak, Mich. “We found that patients generally can resume normal activities the following day with typical side effects.”

The study, which appeared in the Red Journal’s January 2017 issue, presented the results of a nonrandomized, prospective clinical trial of 58 patients with low- or intermediate-risk (non-metastatic) prostate cancer, with a median follow-up period of 2.9 years. All patients received a single, 19 Gy fraction of HDR brachytherapy. The median patient age was 63 years (range 43-73), and 91 percent of the patients presented with stage T1 disease.

At an average of nearly three years following treatment, cancer control rates were favorable and the toxicity profile was highly favorable. Three patients experienced recurrence or progression, yielding an estimated three-year cumulative biochemical control rate of 93 percent. Within the six months following HDR therapy, seven patients (12.1 percent) experienced grade 2 urinary side effects, most commonly frequency/urgency (6.9 percent). No patients experienced short-term grade 3+ urinary toxicity or grade 2+ gastrointestinal (GI) toxicity. Rates were similarly modest for long-term side effects. Six patients (10.3 percent) experienced chronic grade 2 urinary toxicity and one patient (1.7 percent) experienced grade 3 chronic GI toxicity that subsequently resolved. No patients experienced long-term grade 3+ urinary toxicity or grade 4 GI toxicity.

“This study illustrates that a potentially curative dose of radiation may be delivered safely to the prostate entirely in a single administration,” said Krauss.  “Giving the entire dose in a single treatment theoretically could have had a greater negative impact on the normal tissues in close proximity to the prostate—meaning the bladder, urethra and rectum—but this was not found to be the case. Toxicity rates were extremely low, with essentially no major complications encountered in this initial group of 58 patients.”

While findings highlight the potential tolerability of a single fraction of HDR brachytherapy for localized prostate cancer, the article also emphasizes the need for additional follow-up to compare long-term cancer control rates with conventional treatment approaches, which generally administer larger cumulative doses than the 19 Gy dose used in this trial.

“As the follow-up interval lengthens, 19 Gy dosing in a single fraction may or may not be sufficient to result in cure rates comparable to historical standards.  One thing that this study has made clear, however, is that the extremely low toxicity and complication rates leave room to escalate the single fraction dose in subsequent trials,” said Krauss. “While additional study and longer follow-up are necessary to confirm the optimal dose for single-fraction HDR brachytherapy, we are optimistic that the single-treatment approach can eventually become a standard practice for prostate cancer treatment.”

For more information: www.redjournal.org

References

Krauss, D.J., Ye, H., Martinez, A.A., Mitchell, B., et al. "Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy," International Journal of Radiation Oncology, Biology, Physics. Published online Nov. 9, 2016. DOI: http://dx.doi.org/10.1016/j.ijrobp.2016.08.011

Related Content

Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...
Study Finds Multiple Sclerosis Drug Slows Brain Shrinkage

An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Image courtesy of Robert J. Fox, M.D., Cleveland Clinic.

News | Neuro Imaging | August 30, 2018
August 30, 2018 — Results from a clinical...